Citigroup
YMAB

Citigroup’s Y-mAbs Therapeutics YMAB Stock Holding History

Citigroup’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,250
Closed -$68.8K – 6353
2025
Q2 		$68.8K Sell
15,250
-13,268
-47% -$59.6K ﹤0.01% 4607
2025
Q1 		$126K Sell
28,518
-20,713
-42% -$120K ﹤0.01% 4467
2024
Q4 		$385K Buy
49,231
+21,872
+80% +$266K ﹤0.01% 4007
2024
Q3 		$360K Buy
27,359
+18,390
+205% +$233K ﹤0.01% 3941
2024
Q2 		$108K Buy
8,969
+2,224
+33% +$30K ﹤0.01% 4173
2024
Q1 		$110K Buy
6,745
+734
+12% +$9.89K ﹤0.01% 4254
2023
Q4 		$41K Buy
6,011
+5,992
+31,537% +$34.7K ﹤0.01% 4624
2023
Q3 		$103 Sell
19
-10,936
-100% -$63.7K ﹤0.01% 5409
2023
Q2 		$74.4K Sell
10,955
-35,887
-77% -$269K ﹤0.01% 4395
2023
Q1 		$235K Buy
46,842
+45,779
+4,307% +$187K ﹤0.01% 3645
2022
Q4 		$5.19K Sell
1,063
-93,217
-99% -$677K ﹤0.01% 5029
2022
Q3 		$1.36M Buy
94,280
+35,354
+60% +$585K ﹤0.01% 2467
2022
Q2 		$891K Buy
58,926
+28,524
+94% +$333K ﹤0.01% 2757
2022
Q1 		$361K Sell
30,402
-37,353
-55% -$384K ﹤0.01% 3727
2021
Q4 		$1.1M Buy
67,755
+35,999
+113% +$769K ﹤0.01% 3149
2021
Q3 		$906K Sell
31,756
-41,546
-57% -$1.31M ﹤0.01% 3158
2021
Q2 		$2.48M Sell
73,302
-23,651
-24% -$759K ﹤0.01% 2500
2021
Q1 		$2.93M Buy
96,953
+88,812
+1,091% +$3.64M ﹤0.01% 2227
2020
Q4 		$403K Buy
8,141
+4,712
+137% +$218K ﹤0.01% 4398
2020
Q3 		$132K Sell
3,429
-13,651
-80% -$543K ﹤0.01% 4908
2020
Q2 		$738K Buy
17,080
+570
+3% +$21.6K ﹤0.01% 3876
2020
Q1 		$431K Sell
16,510
-1,061
-6% -$30.8K ﹤0.01% 4011
2019
Q4 		$549K Buy
17,571
+16,276
+1,257% +$482K ﹤0.01% 4349
2019
Q3 		$34K Sell
1,295
-5,249
-80% -$134K ﹤0.01% 6386
2019
Q2 		$150K Buy
6,544
+4,685
+252% +$108K ﹤0.01% 5513
2019
Q1 		$49K Buy
1,859
+25
+1% +$549 ﹤0.01% 6359
2018
Q4 		$37K Buy
+1,834
New +$42.1K ﹤0.01% 6479

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's YMAB Position: Q3 2025 in Review

Citigroup sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 15,250 shares — an estimated $68.8K sold.

Citigroup first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $2.93M in Q1 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Citigroup reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 15,250 Y-mAbs Therapeutics shares in Q3 2025, an estimated $68.8K.
  • Citigroup first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
  • Citigroup's Y-mAbs Therapeutics position peaked at $2.93M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.